Tissue Array Specification Sheet
| Product Name: | Multiple organ diseased tissue array, 63 cases/63 cores, replaced by MC631 3 Slides Price: $277 , 5 Slides Price: $452 |
| Array Panel: | Multiple organ diseased tissue microarray, including 63 cases of 18 kinds of organs carcinoma (bladder, brain, breast, colon, esophagus, heart, kidney, liver, lung, ovary, pancreas, prostate, rectum, skin, stomach, testis, thyroid and uterine cervix), single core per case |
| Cat No. |
Cases |
Layout |
Cores |
Diameter |
Thickness |
Standard IHC |
| BC00014 |
63 |
7 x 9 |
63 |
1.5 mm |
5 µm |
Anti-Cytokeratin (CK) confirmed |
Microarray Panel Display
| Legend: | Bla - Bladder,
Bra - Brain,
Bre - Breast,
Col - Colon,
Eso - Esophagus,
Hea - Heart,
Kid - Kidney,
Liv - Liver,
Lun - Lung,
Ova - Ovary,
Pan - Pancreas,
Pro - Prostate,
Rec - Rectum,
Ski - Skin,
Sto - Stomach,
Tes - Testis,
Thr - Thyroid,
Ute - Uterine cervix
- Malignant tumor,
- Benign tumor,
- Hyperplasia,
- Normal tissue
|
Specification Sheet
| Pos |
No. |
Sex |
Age |
Organ |
Pathology diagnosis |
Grade |
TNM |
Type † |
| A1 |
1 |
M |
53 |
Brain |
Astrocytoma |
III |
- |
Malignant |
| A2 |
2 |
M |
62 |
Esophagus |
Squamous cell carcinoma |
III |
- |
Malignant |
| A3 |
3 |
M |
65 |
Stomach |
Adenocarcinoma |
II |
- |
Malignant |
| A4 |
4 |
M |
39 |
Liver |
Hepatocellular carcinoma |
III |
- |
Malignant |
| A5 |
5 |
M |
37 |
Colon |
Adenocarcinoma |
II |
- |
Malignant |
| A6 |
6 |
M |
55 |
Rectum |
Adenocarcinoma |
II |
- |
Malignant |
| A7 |
7 |
M |
66 |
Lung |
Squamous cell carcinoma |
III |
- |
Malignant |
| A8 |
8 |
F |
50 |
Bladder |
Squamous cell carcinoma |
I |
- |
Malignant |
| A9 |
9 |
F |
50 |
Heart |
Myxoma |
- |
- |
Benign |
| B1 |
10 |
M |
25 |
Brain |
Astrocytoma |
II |
- |
Malignant |
| B2 |
11 |
M |
56 |
Esophagus |
Adenocarcinoma |
II |
- |
Malignant |
| B3 |
12 |
M |
71 |
Stomach |
Adenocarcinoma |
II |
- |
Malignant |
| B4 |
13 |
F |
55 |
Liver |
Hepatocellular carcinoma |
II |
- |
Malignant |
| B5 |
14 |
M |
62 |
Colon |
Adenocarcinoma |
II |
- |
Malignant |
| B6 |
15 |
F |
59 |
Rectum |
Adenocarcinoma |
III |
- |
Malignant |
| B7 |
16 |
M |
46 |
Lung |
Squamous cell carcinoma |
III |
- |
Malignant |
| B8 |
17 |
M |
38 |
Bladder |
Squamous cell carcinoma |
II |
- |
Malignant |
| B9 |
18 |
M |
61 |
Heart |
Myxoma |
- |
- |
Benign |
| C1 |
19 |
F |
15 |
Brain |
Astrocytoma |
II |
- |
Malignant |
| C2 |
20 |
F |
72 |
Esophagus |
Squamous cell carcinoma |
I |
- |
Malignant |
| C3 |
21 |
M |
66 |
Stomach |
Adenocarcinoma |
I |
- |
Malignant |
| C4 |
22 |
M |
57 |
Liver |
Cholangiocarcinoma |
- |
- |
Malignant |
| C5 |
23 |
M |
58 |
Colon |
Adenocarcinoma |
I |
- |
Malignant |
| C6 |
24 |
F |
72 |
Rectum |
Adenocarcinoma |
- |
* |
Malignant |
| C7 |
25 |
F |
46 |
Lung |
Squamous cell carcinoma |
II |
- |
Malignant |
| C8 |
26 |
F |
76 |
Bladder |
Squamous cell carcinoma |
I |
- |
Malignant |
| C9 |
27 |
F |
47 |
Heart |
Myxoma |
- |
- |
Benign |
| D1 |
28 |
M |
72 |
Kidney |
Paraganglioma |
- |
- |
Malignant |
| D2 |
29 |
M |
68 |
Thyroid |
Papillary carcinoma |
II |
- |
Malignant |
| D3 |
30 |
F |
54 |
Pancreas |
Adenocarcinoma |
III |
- |
Malignant |
| D4 |
31 |
F |
62 |
Uterus |
Squamous cell carcinoma |
II |
- |
Malignant |
| D5 |
32 |
F |
70 |
Skin |
Squamous cell carcinoma |
III |
- |
Malignant |
| D6 |
33 |
F |
72 |
Breast |
Infiltrating duct carcinoma |
- |
- |
Malignant |
| D7 |
34 |
F |
40 |
Ovary |
Clear cell carcinoma |
- |
- |
Malignant |
| D8 |
35 |
M |
81 |
Prostate |
Adenocarcinoma |
III |
- |
Malignant |
| D9 |
36 |
M |
26 |
Testis |
Lymphoma |
- |
- |
Malignant |
| E1 |
37 |
M |
51 |
Kidney |
Clear cell carcinoma |
- |
- |
Malignant |
| E2 |
38 |
F |
24 |
Thyroid |
Papillary carcinoma |
I |
- |
Malignant |
| E3 |
39 |
F |
62 |
Pancreas |
Fibrous tissue and connective tissue |
- |
- |
Malignant |
| E4 |
40 |
F |
30 |
Uterus |
Squamous cell carcinoma |
II |
- |
Malignant |
| E5 |
41 |
M |
61 |
Skin |
Squamous cell carcinoma |
III |
- |
Malignant |
| E6 |
42 |
F |
45 |
Breast |
Infiltrating duct carcinoma |
- |
- |
Malignant |
| E7 |
43 |
F |
47 |
Ovary |
Malignant Brenner tumor |
- |
- |
Malignant |
| E8 |
44 |
M |
78 |
Prostate |
Adenocarcinoma |
III |
- |
Malignant |
| E9 |
45 |
M |
59 |
Testis |
Seminoma |
- |
- |
Malignant |
| F1 |
46 |
M |
73 |
Kidney |
Clear cell carcinoma |
- |
- |
Malignant |
| F2 |
47 |
F |
55 |
Thyroid |
Thyroid tissue |
- |
- |
Malignant |
| F3 |
48 |
F |
69 |
Pancreas |
Adenocarcinoma |
III |
- |
Malignant |
| F4 |
49 |
F |
30 |
Uterus |
Squamous cell carcinoma |
III |
- |
Malignant |
| F5 |
50 |
M |
73 |
Skin |
Squamous cell carcinoma |
II |
- |
Malignant |
| F6 |
51 |
F |
65 |
Breast |
Infiltrating duct carcinoma |
- |
- |
Malignant |
| F7 |
52 |
F |
49 |
Ovary |
Adenocarcinoma |
III |
- |
Malignant |
| F8 |
53 |
M |
73 |
Prostate |
Adenocarcinoma |
II |
- |
Malignant |
| F9 |
54 |
M |
52 |
Testis |
Seminoma of testicle |
- |
- |
Malignant |
| G1 |
55 |
M |
70 |
Prostate |
Hyperplasia of prostate |
- |
- |
Hyperplasia |
| G2 |
56 |
M |
78 |
Prostate |
Hyperplasia of prostate |
- |
- |
Hyperplasia |
| G3 |
57 |
M |
73 |
Prostate |
Hyperplasia of prostate |
- |
- |
Hyperplasia |
| G4 |
58 |
F |
76 |
Uterine cervix |
Squamous cell carcinoma |
III |
- |
Malignant |
| G5 |
59 |
F |
36 |
Uterine cervix |
Squamous cell carcinoma |
III |
- |
Malignant |
| G6 |
60 |
F |
62 |
Uterine cervix |
Squamous cell carcinoma |
II |
* |
Malignant |
| G7 |
61 |
F |
64 |
Kidney |
Kidney tissue |
- |
- |
Normal |
| G8 |
62 |
F |
33 |
Colon |
Colon mucosa |
- |
- |
Normal |
| G9 |
63 |
M |
60 |
Liver |
Liver tissue |
- |
- |
Normal |
, . † For precise diagnosis, refer to pathology description.
**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.
Staining Scoring: '-' - no staining; '+-' - borderline staining; '+' - weak staining; '++' - moderate staining; '+++' - strong staining; '%' - percentage of positive cells.
TNM grading:
T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum
N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes
M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis